不活化ワクチン市場レポート：2030年までの動向、予測、競合分析

不活化ワクチンの動向と予測

世界の不活化ワクチン市場は、2024年から2030年までのCAGRが5.4%で、2030年までに推定545億米ドルに達すると予想されます。この市場の主な促進要因は、より便利で効果的なワクチンに対する需要の高まり、ワクチン接種を促進するための政府の積極的な取り組み、感染症の流行の増加です。世界の不活化ワクチン市場の将来は、病院、在宅医療、専門クリニックの各市場における機会が有望視されています。

• Lucintelの予測によると、タイプ別では、ウイルス感染予防に有効な不活化ワクチンの需要が大きいため、ウイルス性ワクチンが予測期間中に高い成長を遂げる見込みです。
• 最終用途カテゴリーでは、病院が予測期間中に最も高い成長を示すと予想されます。これは、定期的な予防接種プログラムの一環として、この施設で子供たちに不活化ワクチンを接種する数が増加しているためです。
• 地域別では、アジア太平洋が予測期間中に最も高い成長が見込まれます。これは、感染症の症例が増加していることと、同地域に主要企業が存在するためです。

不活化ワクチン市場の戦略的成長機会

不活化ワクチン市場の市場分析では、さまざまな応用分野における成長機会が特定されています。これらの展望は、世界の健康動向の変化と予防接種の改善を反映しています。

• 新興感染症に対する不活化ワクチンの可能性：新興感染症に対する不活化ワクチンの開発は、成長を促進すると予想されます。新たな病原体との闘いは、国家の健康安全保障と市場拡大にとって極めて重要です。
• 慢性疾患管理における不活化ワクチンの可能性：不活化ワクチンは、がんや糖尿病のような慢性疾患の管理のために研究されています。この用途は、新しいワクチンや治療薬を開発する機会を提供します。
• 小児ワクチン接種における不活化ワクチンの可能性：小児用不活化ワクチンの選択肢を広げることで、さらなる成長機会があります。これらのワクチンは小児の特定のニーズに対応し、予防接種と疾病予防を改善します。
• 旅行・観光分野における不活化ワクチンの可能性：旅行関連疾患に対する不活化ワクチンの需要が高まっています。海外旅行の再開に伴い、現地の風土病から人々を守るワクチンへのニーズが高まっています。
• 生物防御における不活化ワクチンの可能性：バイオテロ防衛のための不活化ワクチン開発への関心も高まっています。これらのワクチンは、バイオテロリズムに対抗し、社会を守るために不可欠です。

こうした成長機会は、不活化ワクチンの幅広い用途を明確にし、その市場性を高め、ヘルスケアシステムの進歩や技術改良の原動力となっています。

不活化ワクチン市場の促進要因・課題

不活化ワクチン市場は、技術的・経済的・規制的要因を含む様々な市場促進要因・課題の影響を受けています。これらの要因を理解することが、市場力学を認識する鍵となります。

不活化ワクチン市場を牽引する要因は以下の通りです：

• 技術的進歩：新しいアジュバントやその他の製剤など、ワクチン製造における最近の技術革新が市場を押し上げています。こうした改良は効率性と安全性において有利であり、ワクチンを患者とヘルスケア提供者の双方にとってより有利なものにしています。
• ワクチン需要の増加：伝染病の罹患率の上昇や保健機関によるキャンペーンが不活化ワクチンの需要を促進しています。この動向は、市場拡大やワクチン開発資金増加の機会をもたらします。
• 規制支援：ワクチンの承認と市場参入には、良好な規制環境が不可欠です。効果的な規制やガイドラインは遅れをなくし、新しい不活化ワクチンがより効率的に市場に投入されることを可能にします。
• ヘルスケア・インフラの改善：保管や流通システムなどのヘルスケア・インフラの強化は、不活化ワクチンをより効果的に投与するのに役立ちます。このネットワークは、地理的に十分なサービスを受けていない地域に到達するために極めて重要です。
• 研究開発への投資：研究開発への投資拡大により、ワクチンの有効性が革新されています。現在進行中のワクチン製剤の研究は、新たな疾病のニーズに対応しています。

不活化ワクチン市場における課題は以下の通り：

• 高い製造コスト：非生存ワクチンの開発・製造には依然としてコストがかかります。こうした高コストは、特に低所得者層における価格設定や入手のしやすさに影響を与える可能性があります。
• 市場競争：ワクチンメーカー間の激しい競合が価格下落の圧力となっており、各社は競争力を維持するために製品の継続的な更新を余儀なくされています。

不活化ワクチン市場は、技術の進歩、需要の増加、支持的な規制枠組みといった重要な促進要因に加え、コンプライアンス、製造コスト、競争に関する課題によって形成されています。これらの要因の役割は、市場の開拓とダイナミクスにおいて極めて重要です。

目次

第1章 エグゼクティブサマリー

第2章 世界の不活化ワクチン市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の不活化ワクチン市場の動向（2018～2023年）と予測（2024～2030年）
• タイプ別：不活化ワクチンの世界市場
  • ウイルス
  • 細菌
  • その他
• 最終用途別：不活化ワクチンの世界市場
  • 病院
  • 在宅ケア
  • 専門クリニック
  • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

• 地域別不活化ワクチンの世界市場
• 北米の不活化ワクチン市場
• 欧州の不活化ワクチン市場
• アジア太平洋地域の不活化ワクチン市場
• その他地域の不活化ワクチン市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • タイプ別の世界の不活化ワクチン市場の成長機会
  • 最終用途別の世界の不活化ワクチン市場の成長機会
  • 地域別の世界の不活化ワクチン市場の成長機会
• 世界の不活化ワクチン市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界の不活化ワクチン市場の生産能力拡大
  • 世界の不活化ワクチン市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Pfizer
• Sanofi
• GlaxoSmithKline
• Merck
• AstraZeneca
• Johnson & Johnson
• CSL Behring

Inactivated Vaccine Trends and Forecast

The future of the global inactivated vaccine market looks promising with opportunities in the hospital, home care, and specialty clinic markets. The global inactivated vaccine market is expected to reach an estimated $54.5 billion by 2030 with a CAGR of 5.4% from 2024 to 2030. The major drivers for this market are the rising demand for more convenient and effective vaccines, supportive government initiatives to promote vaccination, and the increasing prevalence of infectious diseases.

• Lucintel forecasts that, within the type category, viral is expected to witness higher growth over the forecast period due to significant demand for inactivated vaccines given to their effectiveness at preventing viral infections.
• Within the end-use category, the hospital is expected to witness the highest growth over the forecast period due to the increasing number of inactivated vaccinations being administered to children in this facility as part of their regular immunization program.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the augmenting cases of infectious diseases and the presence of key players in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Inactivated Vaccine Market

Certain key trends can be observed in the inactivated vaccine market that are shaping the industry. These trends show improvements in technology, transformations in health needs, and changes in the regulatory environment.

• Emerging Trends in Adjuvant Technology: New adjuvants are being added to existing inactivated vaccines to improve the immune response. These developments are important for enhancing vaccines and providing wider coverage against evolving pathogens.
• Increasing Focus on Vaccine Accessibility: There is an increasing trend to provide inactivated vaccines to all parts of the world, particularly underprivileged countries. This includes actions to increase production and distribution to ensure fair provision of vital vaccines.
• Combination Vaccines: Combination inactivated vaccines for several diseases are becoming more popular. These vaccines help economize immunization schedules and improve patient adherence by reducing the number of doses.
• Incorporation of Digital Health Tools: Monitoring tools, such as tracking apps and digital vaccination records, are being incorporated with inactivated vaccines. These tools help track vaccine placement and improve patient management.
• Stronger Focus on R&D: There is a higher demand for investment in research and development of inactivated vaccines. This trend is driven by the emergence of novel infectious diseases and the need to improve currently available vaccines.

These trends are driving innovation, expanding the role of vaccines, and increasing the efficacy of inactivated vaccines, shaping the future of global vaccination programs.

Recent Developments in the Inactivated Vaccine Market

The inactivated vaccine market has undergone significant changes, indicating advancements in combating diseases with vaccines.

• Expanding the Inactivated Vaccine Pipeline: Recent approvals for inactivated vaccines targeting new pathogens have expanded the market. These vaccines have a better safety profile and address unmet medical needs.
• Streamlined Manufacturing Methods: New production technologies are enabling the efficient manufacture of inactivated vaccines. These innovations help lower prices and make vaccines more accessible, especially in marginalized areas.
• Application of New Quality Vaccine Adjuvants: Efforts are underway to develop new adjuvants that are more efficient and stable than previous ones. These changes are expected to enhance immune memory and reduce the need for boosting.
• Improvement of Distribution Channels: Efforts have increased the distribution of inactivated vaccines globally. Improved logistics and collaborations are enabling vaccines to reach distant and underserved populations.
• Raising Public Health Administration: Public health efforts by governments and organizations are increasing to promote vaccination. These initiatives include education and outreach campaigns alongside immunization efforts to boost vaccine uptake.

These developments enhance the potency of vaccines, lower development costs, and increase accessibility, fostering progress and efficiency in the inactivated vaccine market.

Strategic Growth Opportunities for Inactivated Vaccine Market

Market analysis of the inactivated vaccine market identifies growth opportunities in various application areas. These prospects reflect changing trends in global health and improvements in vaccinations.

• Potential of Inactivated Vaccines for Emerging Infectious Diseases: Developing inactivated vaccines for emerging infectious diseases is expected to drive growth. The fight against new pathogens is critical for national health security and market expansion.
• Potential of Inactivated Vaccines for Chronic Disease Management: Inactivated vaccines are being studied for managing chronic conditions like cancer and diabetes. This application offers opportunities for developing new vaccines and therapeutic agents.
• Potential of Inactivated Vaccines in Pediatric Vaccination: There are additional growth opportunities by expanding inactivated vaccine options for children. These vaccines address specific needs in children, improving immunization and disease prevention.
• Potential of Inactivated Vaccines in Travel and Tourism: There is growing demand for inactivated vaccines for travel-related diseases. As international travel resumes, there is an increased need for vaccines that protect populations from local endemic diseases.
• Potential of Inactivated Vaccines in Biodefense: There is also growing interest in developing inactivated vaccines for bioterrorism defense. These vaccines are vital for combating bioterrorism and protecting society.

These growth opportunities define the wide range of applications for inactivated vaccines, enhancing their marketability and driving progress in healthcare systems and technological improvements.

Inactivated Vaccine Market Driver and Challenges

The market for inactivated vaccines is influenced by a variety of drivers and challenges, including technological, economic, and regulatory factors. Understanding these factors is key to recognizing market dynamics.

The factors driving the inactivated vaccine market include:

• Technological Advancements: Recent innovations in vaccine manufacturing, such as new adjuvants and other formulations, are boosting the market. These improvements offer advantages in efficiency and safety, making vaccines more favorable for both patients and healthcare providers.
• Increased Demand for Vaccines: The rising incidence of communicable diseases and campaigns by health organizations are fueling demand for inactivated vaccines. This trend presents opportunities for market expansion and increased funding for vaccine development.
• Regulatory Support: A favorable regulatory environment is essential for the approval and market entry of vaccines. Effective regulations and guidelines help eliminate delays, allowing new inactivated vaccines to reach the market more efficiently.
• Healthcare Infrastructure Improvements: Enhancements in healthcare infrastructure, such as storage and distribution systems, help administer inactivated vaccines more effectively. This network is crucial for reaching geographically underserved areas.
• Investment in R&D: Increased investment in research and development is driving innovation in vaccine efficacy. Ongoing investigations into vaccine formulations are addressing the needs of new diseases.

Challenges in the inactivated vaccine market include:

• High Production Costs: Non-live vaccines remain expensive to develop and manufacture. These high costs can impact pricing and accessibility, especially in low-income areas.
• Market Competition: Intense competition among vaccine manufacturers is exerting downward pressure on prices and forcing companies to continuously update their products to remain competitive.

The inactivated vaccine market is shaped by significant drivers, such as technological advances, rising demand, and supportive regulatory frameworks, as well as challenges related to compliance, production costs, and competition. The role of these factors is crucial in the development and dynamics of the market.

List of Inactivated Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies inactivated vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the inactivated vaccine companies profiled in this report include-

• Pfizer
• Sanofi
• GlaxoSmithKline
• Merck
• Astrazeneca
• Johnson & Johnson
• CSL Behring

Inactivated Vaccine by Segment

The study includes a forecast for the global inactivated vaccine by type, end use, and region.

Inactivated Vaccine Market by Type [Analysis by Value from 2018 to 2030]:

• Viral
• Bacterial
• Others

Inactivated Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals
• Homecare
• Specialty Clinics
• Others

Inactivated Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Inactivated Vaccine Market

The inactivated vaccine market has made significant progress due to continuous research, policy changes, and global health interest. This is particularly true in countries like the USA, China, India, Germany, and Japan, which share a common goal of improving vaccine safety, efficacy, and availability.

• United States: Recent updates in the U.S. include the approval of new inactivated vaccines to address gaps in immunization for emerging infectious diseases. These vaccines are designed to be more efficient, safer, and cost-effective to manufacture.
• China: China has made significant strides in developing inactivated vaccines for COVID-19 and other infectious diseases. The country is increasing production and enhancing distribution to meet both national and global demands.
• India: India is upgrading its vaccine manufacturing capacity to support the production and use of inactivated vaccines for various diseases. Local manufacturers are aiming to provide low-cost vaccines and improve access in rural communities.
• Japan: Japan has recently introduced new inactivated vaccines for seasonal flu and other viral infections. The country is focusing on improving vaccine safety, effectiveness, and maintaining high manufacturing quality.

Features of the Global Inactivated Vaccine Market

Market Size Estimates: Inactivated vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Inactivated vaccine market size by type, end use, and region in terms of value ($B).

Regional Analysis: Inactivated vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, end uses, and regions for the inactivated vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the inactivated vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the inactivated vaccine market by type (viral, bacterial, and others), end use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Inactivated Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Inactivated Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Inactivated Vaccine Market by Type
  • 3.3.1: Viral
  • 3.3.2: Bacterial
  • 3.3.3: others
• 3.4: Global Inactivated Vaccine Market by End Use
  • 3.4.1: Hospitals
  • 3.4.2: Homecare
  • 3.4.3: Specialty Clinics
  • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Inactivated Vaccine Market by Region
• 4.2: North American Inactivated Vaccine Market
  • 4.2.1: North American Market by Type: Viral, Bacterial, and others
  • 4.2.2: North American Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.3: European Inactivated Vaccine Market
  • 4.3.1: European Market by Type: Viral, Bacterial, and others
  • 4.3.2: European Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.4: APAC Inactivated Vaccine Market
  • 4.4.1: APAC Market by Type: Viral, Bacterial, and others
  • 4.4.2: APAC Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.5: ROW Inactivated Vaccine Market
  • 4.5.1: ROW Market by Type: Viral, Bacterial, and others
  • 4.5.2: ROW Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Inactivated Vaccine Market by Type
  • 6.1.2: Growth Opportunities for the Global Inactivated Vaccine Market by End Use
  • 6.1.3: Growth Opportunities for the Global Inactivated Vaccine Market by Region
• 6.2: Emerging Trends in the Global Inactivated Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Inactivated Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Inactivated Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Sanofi
• 7.3: GlaxoSmithKline
• 7.4: Merck
• 7.5: AstraZeneca
• 7.6: Johnson & Johnson
• 7.7: CSL Behring